Authors: <\/sup>Wulan Panduwi Melasari<\/strong>1<\/sup><\/strong>,<\/strong> Rezlie Bellatasie<\/strong>1<\/sup><\/strong>,Suharjono2<\/sup><\/strong>*<\/sup><\/strong><\/p>\n 1<\/sup><\/em>Master of Clinical Pharmacy, 2<\/sup><\/em>Dep<\/em>artment Of Clinical Pharmacy, <\/em><\/p>\n Faculty of Pharmacy, Airlangga University,<\/em> Surabaya, Indonesia<\/em><\/p>\n Email: <\/em>shj_ms_id@yahoo.com<\/em><\/a> & <\/em>wulanpanduwi21@gmail.com<\/em><\/a><\/p>\n Abstract<\/em><\/strong><\/p>\n Cardiovascular disease is the leading cause of death worldwide and Acute Coronary Syndrome (ACS) is one of the biggest causes of high mortality in CVD. In Indonesia, according to the Deparment of Health survey in 2008, the mortality rate reached 25% due to heart attack. In ACS patient with STEMI, there are two options for reperfusion therapy: percutaneous coronary intervention (PCI) and fibrinolytic\/thrombolytic therapy. The aim of this article review is to discuss reperfusion therapy by comparing PCI and thrombolytic\/fibrinolytic therapy of ACS patients with STEMI conditions. The methods in this review are the search of research results and digital data based on Pubmed, Scopus and Google Scholar. From this review, it can be concluded that primary PCI therapy is the preferred therapy in STEMI patients compared with thrombolytic therapy, except in some conditions such as unsupportive facilities and infrastruktur of the hospitals, then thrombolytic therapy can be performed up to 30 minutes after the attack. <\/em><\/p>\n